Posted by Michael Wonder on 30 Jun 2022
Akeso's cadonilimab (PD-1/CTLA-4), the first dual immune checkpoint inhibitor to treat cancer, approved for marketing in China
29 June 2022 - Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing.
Akeso announced that its PD-1/CTLA-4 bi-specific antibody (cadonilimab, AK104) has received marketing approval from the NMPA of China for the treatment of patients with relapsed or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy.
